PE20140792A1 - Composiciones farmaceuticas - Google Patents
Composiciones farmaceuticasInfo
- Publication number
- PE20140792A1 PE20140792A1 PE2013001327A PE2013001327A PE20140792A1 PE 20140792 A1 PE20140792 A1 PE 20140792A1 PE 2013001327 A PE2013001327 A PE 2013001327A PE 2013001327 A PE2013001327 A PE 2013001327A PE 20140792 A1 PE20140792 A1 PE 20140792A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- quinolin
- halogen
- phenyl
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN COMPUESTO DE FORMULA (I), DONDE R1 ES NAFTILO, FENILO, ENTRE OTROS; R2 ES O O S; R3 ES ALQUILO C1-C7; R4 ES PIRIDILO, HALOGENO, CIANO, ENTRE OTROS; R5 ES H O HALOGENO; n ES 0 O 1; R6 ES OXIDO; R7 ES H O AMINO, b) UN TENSOACTIVO NO IONICO QUE ES LA VITAMINA E TPGS EN UNA CANTIDAD DE 15% A 80% EN PESO DE LA COMPOSICION, c) UN AGENTE MEJORADOR DE DISOLUCION SELECCIONADO DE POLIETILENGLICOL, POLI-OXIDO DE ETILENO Y COMBINACIONES DE LOS MISMOS. ES COMPUESTO PREFERIDO DE FORMULA (I) EL 2-METIL-2-[4-(3-METIL-2-OXO-8-QUINOLIN-3-IL-2,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-1-IL)-FENIL]-PROPIONITRILO O SU SAL DE MONOSILATO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41953810P | 2010-12-03 | 2010-12-03 | |
US201161436324P | 2011-01-26 | 2011-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20140792A1 true PE20140792A1 (es) | 2014-07-09 |
Family
ID=45346568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013001327A PE20140792A1 (es) | 2010-12-03 | 2011-12-01 | Composiciones farmaceuticas |
Country Status (21)
Country | Link |
---|---|
US (1) | US20130245061A1 (es) |
EP (1) | EP2645999A2 (es) |
JP (1) | JP2013544845A (es) |
KR (1) | KR20140010009A (es) |
CN (1) | CN103237544A (es) |
AR (1) | AR084067A1 (es) |
AU (1) | AU2011336478A1 (es) |
CA (1) | CA2817618A1 (es) |
CL (1) | CL2013001557A1 (es) |
CO (1) | CO6801722A2 (es) |
EC (1) | ECSP13012654A (es) |
GT (1) | GT201300144A (es) |
MA (1) | MA34806B1 (es) |
MX (1) | MX2013006187A (es) |
NZ (1) | NZ610467A (es) |
PE (1) | PE20140792A1 (es) |
RU (1) | RU2013130224A (es) |
SG (1) | SG190210A1 (es) |
TW (1) | TW201304779A (es) |
WO (1) | WO2012075253A2 (es) |
ZA (1) | ZA201303223B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013192367A1 (en) * | 2012-06-22 | 2013-12-27 | Novartis Ag | Neuroendocrine tumor treatment |
EP2900219B1 (en) * | 2012-09-27 | 2016-07-06 | Basf Se | A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer |
RS62082B1 (sr) | 2015-04-02 | 2021-08-31 | Merck Patent Gmbh | Imidazolonilhinolini i njihova primena kao inhibitora atm kinaze |
US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
CA3044355A1 (en) | 2016-11-23 | 2018-05-31 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
EP4009973A4 (en) * | 2019-08-07 | 2023-08-23 | Aclipse One, Inc. | PHARMACEUTICAL COMPOSITIONS OF (6AS) -6-METHYL-5,6,6A,7-TETRAHYDRO-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL |
EP4282475A3 (en) * | 2019-12-20 | 2024-02-28 | Intervet International B.V. | A pyrazole pharmaceutical composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
AU2004295061B2 (en) * | 2003-11-21 | 2008-11-20 | Novartis Ag | 1H-imidazoquinoline derivatives as protein kinase inhibitors |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US20080125477A1 (en) * | 2006-05-16 | 2008-05-29 | Decode Genetics, Ehf. | 7-(acryloyl) indole compositions and methods of making and using same |
PE20080766A1 (es) * | 2006-08-30 | 2008-06-15 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
WO2008079629A2 (en) * | 2006-12-21 | 2008-07-03 | Boehringer Ingelheim International Gmbh | Formulations with improved bioavailability |
JP2010519309A (ja) | 2007-02-20 | 2010-06-03 | ノバルティス アーゲー | 脂質キナーゼおよびmTORのデュアル阻害剤としてのイミダゾキノリン |
-
2011
- 2011-12-01 US US13/989,250 patent/US20130245061A1/en not_active Abandoned
- 2011-12-01 PE PE2013001327A patent/PE20140792A1/es not_active Application Discontinuation
- 2011-12-01 KR KR1020137017289A patent/KR20140010009A/ko not_active Application Discontinuation
- 2011-12-01 CN CN2011800576307A patent/CN103237544A/zh active Pending
- 2011-12-01 AU AU2011336478A patent/AU2011336478A1/en not_active Abandoned
- 2011-12-01 CA CA2817618A patent/CA2817618A1/en not_active Abandoned
- 2011-12-01 MX MX2013006187A patent/MX2013006187A/es not_active Application Discontinuation
- 2011-12-01 RU RU2013130224/15A patent/RU2013130224A/ru not_active Application Discontinuation
- 2011-12-01 SG SG2013035480A patent/SG190210A1/en unknown
- 2011-12-01 AR ARP110104478A patent/AR084067A1/es unknown
- 2011-12-01 JP JP2013542171A patent/JP2013544845A/ja active Pending
- 2011-12-01 NZ NZ610467A patent/NZ610467A/en not_active IP Right Cessation
- 2011-12-01 WO PCT/US2011/062837 patent/WO2012075253A2/en active Application Filing
- 2011-12-01 EP EP11794907.3A patent/EP2645999A2/en not_active Withdrawn
- 2011-12-01 MA MA35945A patent/MA34806B1/fr unknown
- 2011-12-02 TW TW100144445A patent/TW201304779A/zh unknown
-
2013
- 2013-05-03 ZA ZA2013/03223A patent/ZA201303223B/en unknown
- 2013-05-30 CO CO13133022A patent/CO6801722A2/es not_active Application Discontinuation
- 2013-05-31 CL CL2013001557A patent/CL2013001557A1/es unknown
- 2013-06-03 EC ECSP13012654 patent/ECSP13012654A/es unknown
- 2013-06-03 GT GT201300144A patent/GT201300144A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201303223B (en) | 2014-01-29 |
CL2013001557A1 (es) | 2013-10-25 |
KR20140010009A (ko) | 2014-01-23 |
AR084067A1 (es) | 2013-04-17 |
MX2013006187A (es) | 2013-07-15 |
WO2012075253A3 (en) | 2012-08-09 |
US20130245061A1 (en) | 2013-09-19 |
ECSP13012654A (es) | 2013-08-30 |
NZ610467A (en) | 2015-01-30 |
TW201304779A (zh) | 2013-02-01 |
CA2817618A1 (en) | 2012-06-07 |
JP2013544845A (ja) | 2013-12-19 |
SG190210A1 (en) | 2013-06-28 |
RU2013130224A (ru) | 2015-01-10 |
CO6801722A2 (es) | 2013-11-29 |
CN103237544A (zh) | 2013-08-07 |
WO2012075253A2 (en) | 2012-06-07 |
EP2645999A2 (en) | 2013-10-09 |
MA34806B1 (fr) | 2014-01-02 |
AU2011336478A1 (en) | 2013-06-06 |
GT201300144A (es) | 2014-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20140792A1 (es) | Composiciones farmaceuticas | |
PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
CY1120994T1 (el) | Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων | |
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
PE20190111A1 (es) | Nuevos derivados aminoacido, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
AR062282A1 (es) | Composiciones colorantes | |
PE20191652A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
AR062074A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
PE20170775A1 (es) | Derivados de benzodiazepina citotoxicos | |
AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
PE20080123A1 (es) | Composiciones farmaceuticas que contienen vx-950 en el tratamiento de hepatitis c | |
ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
UY30296A1 (es) | Compuestos fenil amido heterociclicos condensados | |
AR076859A1 (es) | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
PE20200608A1 (es) | Nuevos derivados de azaquinolina | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
BR112019003945A2 (pt) | composições oftálmicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |